혈장 단백질 치료제 시장 규모는 2023년 250억 7,000만 달러에 달했습니다. 이 시장은 2024년부터 2030년까지 예측 기간 동안 6.65%의 연평균 복합 성장률(CAGR)로 성장하여 2030년에는 392억 7,000만 달러에 달할 것으로 예측됩니다. 혈장 단백질 치료제 시장은 혈우병, 다발성 경화증, 면역성 혈소판 감소증 등 다양한 질환의 관리에 필수 응고인자 공급, 면역 반응 조절, 환자 예후 개선 등 혈장 단백질 치료제가 중요한 역할을 수행함에 따라 크게 성장하고 있습니다. 이러한 치료법의 지속적인 발전과 적용 범위의 확대는 2024년부터 2030년까지 예측 기간 동안 이 시장의 상당한 성장을 가속할 것으로 예상됩니다.
세계혈우병연맹(2022년)의 보고에 따르면, 전 세계적으로 매년 약 2만 명의 혈우병 환자가 태어나고 있으며, 그 중 약 7,000명이 중증으로 분류됩니다. 이 외에도 혈우병 환자는 23만 3,577명이며, 그 중 혈우병 A가 18만 5,318명, 혈우병 B가 3만 7,998명인 것으로 나타났습니다.
세계보건기구(WHO) 데이터(2023년)에 따르면, 전 세계적으로 180만 명 이상이 다발성 경화증(MS)을 앓고 있는 것으로 보고되고 있습니다. 다발성 경화증은 인지, 감정, 운동, 감각, 시각 등 다양한 기능에 영향을 미치며, 다발성 경화증 치료에는 혈장 단백질 요법, 특히 면역글로불린 정맥주사 요법(IVIG)이 면역 체계를 조절하고 염증을 억제하기 위해 사용되며, IVIG는 신경 주위의 수초를 공격하는 자가면역 반응을 억제하고 재발 빈도와 중증도를 감소시킬 수 있으며, 재발 빈도와 중증도를 감소시킬 수 있습니다.
미국희귀질환기구에 따르면 면역성 혈소판감소증(ITP)은 생후 3개월부터 100세 이상까지 모든 연령대의 사람들이 걸릴 수 있으며, ITP 진단을 받은 환자의 약 40%가 10세 미만의 어린이라고 합니다. 전 세계적으로 20만 명 이상이 이 질환을 앓고 있는 것으로 추정됩니다. 혈장 단백질 요법, 특히 정맥 내 면역글로불린 요법(IVIG)은 혈소판 수를 증가시키고 면역 매개 혈소판 파괴를 감소시키는 데 사용되며, 면역 체계를 조절하기 위해 풀링된 항체를 제공하여 혈소판 수치를 빠르게 개선하고 출혈을 예방하기 위해 일반적으로 급성 또는 중증의 경우에 사용됩니다. 또는 중증 질환에 주로 사용됩니다.
따라서 위의 모든 요인들이 종합적으로 2024년부터 2030년까지의 예측 기간 동안 전체 혈장 단백질 치료제 시장을 견인할 것으로 보입니다.
이 보고서는 세계 혈장 단백질 치료제 시장을 조사했으며, 시장 개요와 함께 제품별/용도별/지역별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.
Plasma Protein Therapeutics Market by Product (Immunoglobulin, Albumin, Plasma Derived Factor VIII, and Others), Application (Hemophilia, Idiopathic Thrombocytopenic, Primary Immunodeficiencies, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the rising cases of autoimmune & neurological disorders and the increasing product developmental activities across the globe.
The plasma protein therapeutics market was valued at USD 25.07 billion in 2023, growing at a CAGR of 6.65% during the forecast period from 2024 to 2030 to reach USD 39.27 billion by 2030. The plasma protein therapeutics market is growing significantly due to the critical role plasma protein therapeutics play in managing diverse conditions such as hemophilia, multiple sclerosis, and immune thrombocytopenia by providing essential clotting factors, modulating immune responses, and improving patient outcomes. The ongoing advancements in these therapies and their expanding applications are expected to drive significant growth in the plasma protein therapeutics market during the forecast period from 2024 to 2030.
Plasma Protein Therapeutics Market Dynamics:
According to the World Federation of Haemophilia (2022) reports, approximately 20,000 people with hemophilia are born each year worldwide, with about 7,000 of these cases being classified as severe. In addition to this, the source further stated that there are 233,577 individuals with hemophilia, comprising 185,318 with Hemophilia A and 37,998 with Hemophilia B.
The report also highlighted the global distribution of factor VIII utilization globally, with Africa at 17%, Americas at 17%, Europe at 10%, South East Asia at 36%, Eastern Mediterranean at 11%, and Western Pacific at 9%. Plasma protein therapies, especially factor VIII, are crucial for managing hemophilia worldwide. In regions like Africa, the Americas, South East Asia, Europe, the Eastern Mediterranean, and the Western Pacific, these therapies provide essential clotting factors for treating hemophilia A and B, preventing and managing bleeding episodes, and ensuring effective disease management.
As per data from the World Health Organization (2023), it was reported that over 1.8 million people worldwide are affected by Multiple sclerosis (MS). It impacts various functions including cognitive, emotional, motor, sensory, and visual abilities. In the treatment of MS, plasma protein therapy, particularly intravenous immunoglobulin (IVIG), is used to modulate the immune system and reduce inflammation. IVIG helps to suppress the autoimmune response attacking the myelin sheath around nerves, potentially reducing relapse frequency and severity.
The National Organization for Rare Disorders in 2022, stated that immune thrombocytopenia (ITP) can affect individuals of all ages, ranging from as young as 3 months to over 100 years old. Approximately 40% of those diagnosed with ITP are children under the age of 10. Globally, it is estimated that more than 200,000 people are affected by this condition. Plasma protein therapy, specifically intravenous immunoglobulin (IVIG), is used to increase platelet counts and reduce immune-mediated platelet destruction. IVIG works by providing pooled antibodies to modulate the immune system and is typically employed in acute or severe cases to quickly improve platelet levels and prevent bleeding.
Therefore, all the factors stated above collectively will drive the overall plasma protein therapeutics market during the forecast period from 2024 to 2030.
However, stringent regulations for managing plasma protein products, and severe allergic reactions associated with the administration of plasma, among others may limit their end-user base, thus acting as key constraints limiting the growth of the plasma protein therapeutics.
Plasma Protein Therapeutics Market Segment Analysis:
Plasma Protein Therapeutics Market by Product (Immunoglobulin, Albumin, Plasma Derived Factor VIII, and Others), Application (Hemophilia, Idiopathic Thrombocytopenic, Primary Immunodeficiencies, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the application segment of plasma protein therapeutics, the hemophilia category is expected to have a significant revenue share in the year 2023. The rapid growth of this product category can be attributed to the increased prevalence and awareness of hemophilia have led to the greater recognition and diagnosis of the condition.
This is further facilitated by advancements in genetic testing and screening technologies that enable earlier and more precise identification of the disorder. Continuous innovations in treatment options including the development of extended half-life clotting factors and recombinant therapies, have significantly improved treatment outcomes and patient compliance. These advancements not only enhance the effectiveness of therapies but also reduce the frequency of infusions, making them more convenient for patients.
Additionally, the growth of the application segment is anticipated to be driven by increasing research and development (R&D) activities and advancements by key companies. For example, in July 2021, Sanofi showcased new clinical data and research from its portfolio of marketed and investigational therapies for rare blood disorders, including hemophilia, immune thrombocytopenia (ITP), and acquired thrombotic thrombocytopenic purpura (aTTP).
Therefore, owing to all the above-mentioned factors, the demand for the hemophilia category upsurges, thereby the category is expected to witness considerable growth in the overall plasma protein therapeutics market.
North America is expected to dominate the overall plasma protein therapeutics market:
Among all the regions, North America is expected to dominate the plasma protein therapeutics market in the year 2023 and is expected to do the same during the forecast period. This is due to the increasing prevalence of conditions like Guillain-Barre Syndrome and the growing demand for effective treatments, coupled with strategic partnerships and regulatory advancements. The continuous development and approval of new plasma protein therapies are expected to significantly boost the market for plasma protein therapeutics in North America during the forecast period from 2024 to 2030.
According to data from the Centers of Disease Control and Prevention (2023), it stated that Guillain-Barre Syndrome (GBS) is a rare disorder in which the body's immune system mistakenly attacks the peripheral nerves. This damage to the nerves leads to muscle weakness and, in some cases, paralysis. The exact cause of GBS is not fully understood, but it frequently occurs following an infection with a virus or bacteria. In the United States, an estimated 3,000 to 6,000 people develop GBS each year. In GBS, plasma protein therapy, particularly intravenous immunoglobulin (IVIG), is used as a primary treatment. IVIG helps modulate the immune system by providing pooled antibodies from multiple donors, which can neutralize harmful antibodies attacking the peripheral nerves. This therapy reduces inflammation and supports nerve recovery, often leading to improved functional outcomes.
Various strategic partnerships and collaborations among biotech companies, pharmaceutical firms, and research institutions in North America are also expected to drive the market. For instance, in September 2022, Grifols announced that it signed a pioneering long-term agreement with Canadian Blood Services, Canada's national blood authority, to greatly increase the country's self-sufficiency in immunoglobulin (Ig) medicines, essential plasma-protein therapies used to treat a wide range of immunodeficiencies and other medical conditions.
Rising product developmental activities by regulatory bodies in the region will further boost the market for plasma protein therapeutics. For example, in June 2021, Kedrion Biopharma and Kamada Ltd., two leading biopharmaceutical companies specializing in plasma-derived protein therapeutics, announced that the U.S. Food and Drug Administration (FDA) approved a label update for KEDRAB(R) (Rabies Immune Globulin [Human]).
Therefore, the interplay of all the aforementioned factors is expected to provide a conducive growth environment for the North American plasma protein therapeutics market.
Plasma Protein Therapeutics Market key players:
Some of the key market players operating in the plasma protein therapeutics market include Octapharma AG, Takeda Pharmaceutical Company Limited, Biotest AG, Grifols, S.A., CSL, Bayer AG, Baxter, Bio Products Laboratory Ltd, Kedrion S.p.A, China Biologic Products Holdings, Inc, and others.
Recent Developmental Activities in the Plasma Protein Therapeutics Market:
Key Takeaways from the Plasma Protein Therapeutics Market Report Study
Target audience who can be benefited from this Plasma Protein Therapeutics Market Report Study
Frequently Asked Questions for the Plasma Protein Therapeutics Market:
Plasma protein therapeutics are biologic medications derived from human plasma, consisting of purified plasma proteins such as clotting factors, immunoglobulins, and albumin, used to treat specific deficiencies or dysfunctions of these proteins in various medical conditions.
The plasma protein therapeutics market was valued at USD 25.07 billion in 2023, growing at a CAGR of 6.65% during the forecast period from 2024 to 2030 to reach USD 39.27 billion by 2030.
The plasma protein therapeutics market is growing significantly due to the critical role plasma protein therapeutics play in managing diverse conditions such as hemophilia, multiple sclerosis, and immune thrombocytopenia by providing essential clotting factors, modulating immune responses, and improving patient outcomes. The ongoing advancements in these therapies and their expanding applications are expected to drive significant growth in the plasma protein therapeutics market from 2024 to 2030.
Some of the key market players operating in the plasma protein therapeutics market include Octapharma AG, Takeda Pharmaceutical Company Limited, Biotest AG, Grifols, S.A., CSL, Bayer AG, Baxter, Bio Products Laboratory Ltd, Kedrion S.p.A, China Biologic Products Holdings, Inc, and others.
Among all the regions, North America is estimated to hold a significant revenue share in the plasma protein therapeutics market. This can be ascribed to the increasing prevalence of conditions like Guillain-Barre Syndrome and the growing demand for effective treatments, coupled with strategic partnerships and regulatory advancements. The continuous development and approval of new plasma protein therapies are expected to significantly boost the market for plasma protein therapeutics in North America during the forecast period from 2024 to 2030.